Article | August 6, 2021

Unpacking The Complexity Of In Vitro Intestinal Models

Source: Altis Biosystems

By Christopher Sims, MD, President & Co-Founder

Cell and Gene genetic lab iStock-1209892070

The struggle for companies to successfully transition promising preclinical research to late-stage clinical trials has existed for decades. Roughly 85–90% of drug candidates either display toxic side effects or fail to show efficacy once they are tested in real-world conditions. Rectifying this issue would lead to a massive growth in efficiency for pharmaceutical companies, reducing costs and freeing resources to invest in other innovations. It is here that Altis Biosystems can enhance the robustness of preclinical research, improving the quality of predictive models so that researchers can have increased confidence in the viability of drug candidates as they progress into clinical trials.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online